The Top 5 Biosimilar Articles for the Week of November 1
Here are the top 5 biosimilar articles for the week of November 1, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of November 1, 2021.
Number 5: Patients with and without experience with tumor necrosis factor (TNF)–blocker biologics have incomplete knowledge of biosimilars for these agents, according to findings presented at the Academy of Managed Care Pharmacy (AMCP) 2021 Nexus meeting.
Number 4: Year-over-year biosimilar revenues climbed 10% at Biocon Biologics amid a general reduction in income (-18%), the company said in an earnings statement.
Number 3: Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to much more robust savings in recent years, said Leslie Fish, RPh, PharmD, vice president of pharmacy at IPD Analytics, at the AMCP 2021 Nexus meeting.
Number 2: An Emory pharmacy expert talked about the timing of switching to biosimilars, the Biosimilars Forum recommends biosimilars incentives, and Samsung Bioepis reaches a milestone.
Number 1: The arrival of Susvimo, an ocular implant for treatment of macular degeneration, poses a challenge for ophthalmic reference products and biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
